{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:41:16Z","timestamp":1790232076316,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T00:00:00Z","timestamp":1545696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jbo.2018.100215","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T02:37:45Z","timestamp":1545791865000},"page":"100215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data"],"prefix":"10.1016","volume":"14","author":[{"given":"Christopher","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0968-5096","authenticated-orcid":false,"given":"Lori","family":"Cyprien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini K.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2018.100215_bib0001","first-page":"423","article-title":"Multiple myeloma in the very elderly patient: challenges and solutions","volume":"11","author":"Willan","year":"2016","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.jbo.2018.100215_bib0002","unstructured":"SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"10.1016\/j.jbo.2018.100215_bib0003","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood. Adv."},{"key":"10.1016\/j.jbo.2018.100215_bib0004","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.jbo.2018.100215_bib0005","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.100215_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J. Bone. Oncol."},{"key":"10.1016\/j.jbo.2018.100215_bib0007","first-page":"285","article-title":"Myeloma bone disease: pathogenesis and treatment","volume":"15","author":"O'Donnell","year":"2017","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.jbo.2018.100215_bib0008","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2018.100215_bib0009","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer. Treat. Rev."},{"key":"10.1016\/j.jbo.2018.100215_bib0010","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1182\/blood.V122.21.3090.3090","article-title":"Skeletal-related events in patients with multiple myeloma in the era of novel agents: low incidence of pathological fractures after treatment","volume":"122","author":"Terpos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2018.100215_bib0011","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.100215_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: a case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J. Exp. Clin. Cancer. Res."},{"key":"10.1016\/j.jbo.2018.100215_bib0013","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support. Care. Cancer"},{"key":"10.1016\/j.jbo.2018.100215_bib0014","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3111\/13696998.2015.1132225","article-title":"Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma","volume":"19","author":"Nash Smyth","year":"2016","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.jbo.2018.100215_bib0015","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"10.1016\/j.jbo.2018.100215_bib0016","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","article-title":"Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"36","author":"Anderson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2018.100215_bib0017","unstructured":"National Comprehensive Care Network. NCCN Clinical Practice Guidelines in Oncology \u2013 Multiple Myeloma Version 4.2018. 2018."},{"key":"10.1016\/j.jbo.2018.100215_bib0018","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2018.100215_bib0019","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbo.2018.100215_bib0020","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2018.100215_bib0021","series-title":"(Denosumab) [package insert]","year":"2018"},{"key":"10.1016\/j.jbo.2018.100215_bib0022","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.jbo.2018.100215_bib0023","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2018.100215_bib0024","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00223-017-0349-1","article-title":"The proteasome and myeloma-associated bone disease","volume":"102","author":"Accardi","year":"2018","journal-title":"Calcif. Tissue. Int."},{"key":"10.1016\/j.jbo.2018.100215_bib0025","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0609.2011.01599.x","article-title":"Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma","volume":"86","author":"Delforge","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jbo.2018.100215_bib0026","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/leu.2013.267","article-title":"VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT","volume":"28","author":"Terpos","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2018.100215_bib0027","first-page":"87","article-title":"Low incidence of skeletal-related events at the time of first relapse in patients with multiple myeloma who received bortezomib-based regimens as first line treatment","volume":"101","author":"Terpos","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jbo.2018.100215_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12874-015-0047-5","article-title":"Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods","volume":"15","author":"Aly","year":"2015","journal-title":"BMC. Med. Res. Methodol."},{"key":"10.1016\/j.jbo.2018.100215_bib0029","first-page":"2833","article-title":"Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data","volume":"26","author":"Kim","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jbo.2018.100215_bib0030","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V122.21.3158.3158","article-title":"Skeletal-related events in myeloma: a population-based study","volume":"122","author":"Ashcroft","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2018.100215_bib0031","doi-asserted-by":"crossref","first-page":"A413","DOI":"10.1016\/j.jval.2017.08.093","article-title":"Patient characteristics, skeletal related events (SRE) and renal impairment (RI) in patients with multiple myeloma (MM): a patient chart audit in EU5","volume":"20","author":"Mateos","year":"2017","journal-title":"Value. Health"},{"key":"10.1016\/j.jbo.2018.100215_bib0032","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/MLR.0b013e3181808c05","article-title":"Identification and validation of vertebral compression fractures using administrative claims data","volume":"47","author":"Curtis","year":"2009","journal-title":"Med. Care"},{"key":"10.1016\/j.jbo.2018.100215_bib0033","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/1471-2458-12-301","article-title":"Osteoporosis-related fracture case definitions for population-based administrative data","volume":"12","author":"Lix","year":"2012","journal-title":"BMC. Public. Health"},{"key":"10.1016\/j.jbo.2018.100215_bib0034","first-page":"30","article-title":"A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents","volume":"6","author":"Ria","year":"2013","journal-title":"Int. J. Clin. Exp. Med."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418302781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137418302781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:49Z","timestamp":1761941809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137418302781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":34,"alternative-id":["S2212137418302781"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2018.100215","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2018.100215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100215"}}